Biologics and Biosimilars Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
MARKET INTRODUCTION Mrinal Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Biosimilars are similar to reference drugs. However, they exhibit a minor difference in clinically inactive components. They are identical in terms of safety, effectiveness, and clinical significance as their reference product. Biologics are produced from living organisms by using complex manufacturing processes. A wide variety of biologics are available such as monoclonal antibodies, therapeutic proteins, vaccines, and others. These are active substances obtained from living cells of plants or animals. Biosimilars are approximately 20-25% cheaper than their reference/branded products. Moreover, biologics are used in the treatment of a wide variety of indications such as osteoporosis, arthritis, cystic fibrosis, autoimmune disorders, and cancer. For instance, some of the approved biosimilars are Mvasi (Avastin), Erelzi (Enbrel), Ogivri (Herceptin), Amjevita (Amjevita), among others.
MARKET DYNAMICS
In the last two decades, the biotechnology industry developed a wide range of biologic drugs, changing the medicine landscape worldwide. Biologics are being successfully being used to treat many chronic diseases. The increasing availability of biosimilars is contributing to the growth of the market. For instance, Biogen, which is a prominent manufacturer of biosimilar therapies, offers an anti-TNF therapies portfolio. These are used for the treatment of various inflammatory conditions like rheumatoid arthritis, bowel disease, psoriatic arthritis, among others. Biosimilars are helping in expanding cost-effective treatment options for chronic diseases. Increasing cases of life-threatening diseases are growing demand for such therapies. Additionally, emerging markets such as China, India, are broadening the scope of the market and presenting growth opportunities for future growth.
MARKET SCOPE
The "Global Biologics and Biosimilars Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of biologics and biosimilars market with detailed market segmentation by product, application and geography. The global biologics and biosimilars market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading biologics and biosimilars market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global biologics and biosimilars market is segmented on the basis of product and application. Based on product, the market is segmented as recombinant glycosylated proteins, recombinant non-glycosylated proteins and recombinant peptides. Recombinant glycosylated proteins are further sub segmented into monoclonal antibodies, erythroprotein, and others. Recombinant non-glycosylated proteins are further sub divided into insulin, Granulocyte Colony-stimulating Factor, and interferon. Based on indication, the market is segmented as chronic diseases, oncology, autoimmune diseases, infectious diseases, blood disorders, growth hormone deficiency and other.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global biologics and biosimilars market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The biologics and biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting biologics and biosimilars market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the biologics and biosimilars market in these regions.
Have a question?
Speak to Analyst
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global biologics and biosimilars market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The biologics and biosimilars market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting biologics and biosimilars market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the biologics and biosimilars market in these regions.
MARKET PLAYERS
The report covers key developments in the biologics and biosimilars market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from biologics and biosimilars market are anticipated to lucrative growth opportunities in the future with the rising demand for biologics and biosimilars market in the global market. Below mentioned is the list of few companies engaged in the biologics and biosimilars market.
The report also includes the profiles of key biologics and biosimilars market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Pfizer Inc.
- Intas Pharmaceuticals Ltd.
- Biocon
- Dr. Reddy's Laboratories Ltd.
- Sandoz International GmbH (Novartis division)
- CELLTRION INC.
- Amgen Inc.
- STADA Arzneimittel AG
- Apotex Inc.
- Biogen
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Biologics And Biosimilars Market - By Product
1.3.2 Biologics And Biosimilars Market - By Indication
1.3.3 Biologics And Biosimilars Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. BIOLOGICS AND BIOSIMILARS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. BIOLOGICS AND BIOSIMILARS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. BIOLOGICS AND BIOSIMILARS MARKET - GLOBAL MARKET ANALYSIS
6.1. BIOLOGICS AND BIOSIMILARS - GLOBAL MARKET OVERVIEW
6.2. BIOLOGICS AND BIOSIMILARS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. BIOLOGICS AND BIOSIMILARS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. RECOMBINANT GLYCOSYLATED PROTEINS
7.3.1. Overview
7.3.2. Recombinant Glycosylated Proteins Market Forecast and Analysis
7.3.3. Monoclonal Antibodies Market
7.3.3.1. Overview
7.3.3.2. Monoclonal Antibodies Market Forecast and Analysis
7.3.4. Erythroprotein Market
7.3.4.1. Overview
7.3.4.2. Erythroprotein Market Forecast and Analysis
7.3.5. Others Market
7.3.5.1. Overview
7.3.5.2. Others Market Forecast and Analysis
7.4. RECOMBINANT NON-GLYCOSYLATED PROTEINS
7.4.1. Overview
7.4.2. Recombinant Non-Glycosylated Proteins Market Forecast and Analysis
7.4.3. Insulin Market
7.4.3.1. Overview
7.4.3.2. Insulin Market Forecast and Analysis
7.4.4. Granulocyte Colony-stimulating Factor Market
7.4.4.1. Overview
7.4.4.2. Granulocyte Colony-stimulating Factor Market Forecast and Analysis
7.4.5. Interferon Market
7.4.5.1. Overview
7.4.5.2. Interferon Market Forecast and Analysis
8. BIOLOGICS AND BIOSIMILARS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION
8.1. OVERVIEW
8.2. INDICATION MARKET FORECASTS AND ANALYSIS
8.3. CHRONIC DISEASES
8.3.1. Overview
8.3.2. Chronic Diseases Market Forecast and Analysis
8.4. ONCOLOGY
8.4.1. Overview
8.4.2. Oncology Market Forecast and Analysis
8.5. AUTOIMMUNE DISEASES
8.5.1. Overview
8.5.2. Autoimmune Diseases Market Forecast and Analysis
8.6. INFECTIOUS DISEASES
8.6.1. Overview
8.6.2. Infectious Diseases Market Forecast and Analysis
8.7. BLOOD DISORDERS
8.7.1. Overview
8.7.2. Blood Disorders Market Forecast and Analysis
8.8. GROWTH HORMONE DEFICIENCY
8.8.1. Overview
8.8.2. Growth Hormone Deficiency Market Forecast and Analysis
8.9. OTHER
8.9.1. Overview
8.9.2. Other Market Forecast and Analysis
9. BIOLOGICS AND BIOSIMILARS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Biologics And Biosimilars Market Overview
9.1.2 North America Biologics And Biosimilars Market Forecasts and Analysis
9.1.3 North America Biologics And Biosimilars Market Forecasts and Analysis - By Product
9.1.4 North America Biologics And Biosimilars Market Forecasts and Analysis - By Indication
9.1.5 North America Biologics And Biosimilars Market Forecasts and Analysis - By Countries
9.1.5.1 United States Biologics And Biosimilars Market
9.1.5.1.1 United States Biologics And Biosimilars Market by Product
9.1.5.1.2 United States Biologics And Biosimilars Market by Indication
9.1.5.2 Canada Biologics And Biosimilars Market
9.1.5.2.1 Canada Biologics And Biosimilars Market by Product
9.1.5.2.2 Canada Biologics And Biosimilars Market by Indication
9.1.5.3 Mexico Biologics And Biosimilars Market
9.1.5.3.1 Mexico Biologics And Biosimilars Market by Product
9.1.5.3.2 Mexico Biologics And Biosimilars Market by Indication
9.2. EUROPE
9.2.1 Europe Biologics And Biosimilars Market Overview
9.2.2 Europe Biologics And Biosimilars Market Forecasts and Analysis
9.2.3 Europe Biologics And Biosimilars Market Forecasts and Analysis - By Product
9.2.4 Europe Biologics And Biosimilars Market Forecasts and Analysis - By Indication
9.2.5 Europe Biologics And Biosimilars Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Biologics And Biosimilars Market
9.2.5.1.1 Germany Biologics And Biosimilars Market by Product
9.2.5.1.2 Germany Biologics And Biosimilars Market by Indication
9.2.5.2 France Biologics And Biosimilars Market
9.2.5.2.1 France Biologics And Biosimilars Market by Product
9.2.5.2.2 France Biologics And Biosimilars Market by Indication
9.2.5.3 Italy Biologics And Biosimilars Market
9.2.5.3.1 Italy Biologics And Biosimilars Market by Product
9.2.5.3.2 Italy Biologics And Biosimilars Market by Indication
9.2.5.4 Spain Biologics And Biosimilars Market
9.2.5.4.1 Spain Biologics And Biosimilars Market by Product
9.2.5.4.2 Spain Biologics And Biosimilars Market by Indication
9.2.5.5 United Kingdom Biologics And Biosimilars Market
9.2.5.5.1 United Kingdom Biologics And Biosimilars Market by Product
9.2.5.5.2 United Kingdom Biologics And Biosimilars Market by Indication
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Biologics And Biosimilars Market Overview
9.3.2 Asia-Pacific Biologics And Biosimilars Market Forecasts and Analysis
9.3.3 Asia-Pacific Biologics And Biosimilars Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Biologics And Biosimilars Market Forecasts and Analysis - By Indication
9.3.5 Asia-Pacific Biologics And Biosimilars Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Biologics And Biosimilars Market
9.3.5.1.1 Australia Biologics And Biosimilars Market by Product
9.3.5.1.2 Australia Biologics And Biosimilars Market by Indication
9.3.5.2 China Biologics And Biosimilars Market
9.3.5.2.1 China Biologics And Biosimilars Market by Product
9.3.5.2.2 China Biologics And Biosimilars Market by Indication
9.3.5.3 India Biologics And Biosimilars Market
9.3.5.3.1 India Biologics And Biosimilars Market by Product
9.3.5.3.2 India Biologics And Biosimilars Market by Indication
9.3.5.4 Japan Biologics And Biosimilars Market
9.3.5.4.1 Japan Biologics And Biosimilars Market by Product
9.3.5.4.2 Japan Biologics And Biosimilars Market by Indication
9.3.5.5 South Korea Biologics And Biosimilars Market
9.3.5.5.1 South Korea Biologics And Biosimilars Market by Product
9.3.5.5.2 South Korea Biologics And Biosimilars Market by Indication
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Biologics And Biosimilars Market Overview
9.4.2 Middle East and Africa Biologics And Biosimilars Market Forecasts and Analysis
9.4.3 Middle East and Africa Biologics And Biosimilars Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Biologics And Biosimilars Market Forecasts and Analysis - By Indication
9.4.5 Middle East and Africa Biologics And Biosimilars Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Biologics And Biosimilars Market
9.4.5.1.1 South Africa Biologics And Biosimilars Market by Product
9.4.5.1.2 South Africa Biologics And Biosimilars Market by Indication
9.4.5.2 Saudi Arabia Biologics And Biosimilars Market
9.4.5.2.1 Saudi Arabia Biologics And Biosimilars Market by Product
9.4.5.2.2 Saudi Arabia Biologics And Biosimilars Market by Indication
9.4.5.3 U.A.E Biologics And Biosimilars Market
9.4.5.3.1 U.A.E Biologics And Biosimilars Market by Product
9.4.5.3.2 U.A.E Biologics And Biosimilars Market by Indication
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Biologics And Biosimilars Market Overview
9.5.2 South and Central America Biologics And Biosimilars Market Forecasts and Analysis
9.5.3 South and Central America Biologics And Biosimilars Market Forecasts and Analysis - By Product
9.5.4 South and Central America Biologics And Biosimilars Market Forecasts and Analysis - By Indication
9.5.5 South and Central America Biologics And Biosimilars Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Biologics And Biosimilars Market
9.5.5.1.1 Brazil Biologics And Biosimilars Market by Product
9.5.5.1.2 Brazil Biologics And Biosimilars Market by Indication
9.5.5.2 Argentina Biologics And Biosimilars Market
9.5.5.2.1 Argentina Biologics And Biosimilars Market by Product
9.5.5.2.2 Argentina Biologics And Biosimilars Market by Indication
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. BIOLOGICS AND BIOSIMILARS MARKET, KEY COMPANY PROFILES
11.1. PFIZER INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. INTAS PHARMACEUTICALS LTD.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. BIOCON
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. DR. REDDY’S LABORATORIES LTD.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. SANDOZ INTERNATIONAL GMBH (NOVARTIS DIVISION)
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. CELLTRION INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. AMGEN INC.
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. STADA ARZNEIMITTEL AG
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. APOTEX INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. BIOGEN
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies
1. Pfizer Inc.
2. Intas Pharmaceuticals Ltd.
3. Biocon
4. Dr. Reddy's Laboratories Ltd.
5. Sandoz International GmbH (Novartis division)
6. CELLTRION INC.
7. Amgen Inc.
8. STADA Arzneimittel AG
9. Apotex Inc.
10. Biogen
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For